AI chatbot aims to demystify prostate cancer radiation — a trial puts it to the test

NCT ID NCT07719062

Not yet recruiting Symptom relief Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether an artificial intelligence chatbot can help men with prostate cancer better understand radiation therapy. Participants will use a plain-language chatbot alongside standard education from their care team. Researchers will measure changes in patients' confidence in managing symptoms and their overall understanding of treatment. The goal is to see if AI can make complex medical information more accessible without replacing conversations with doctors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an AI-powered educational chatbot that provides plain-language information about prostate cancer radiation therapy
What this could lead to: If it works, this could point toward a simple, scalable way to help patients feel more informed and confident before cancer treatment.
What could go wrong: This is a small, early-stage study with only 50 participants. The chatbot is not a substitute for medical advice, and its answers may sometimes be incomplete or unclear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PATIENTS

More trials for these conditions

Other studies related to the condition(s) this trial covers.